Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Clotet

Showing results (241-250 of 263) with videos related to

Pageof 27
Sort By:
The Journal of Antimicrobial Chemotherapy|December 26, 2015
Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ARTS Lambert-Niclot, E C George, A Pozniak, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|September 13, 2012
Optimal timing for initiation of highly active antiretroviral therapy in treatment-naïve human immunodeficiency virus-1-infected individuals presenting with AIDS-defining diseases: the experience of the PISCIS CohortC Manzardo, A Esteve, N Ortega, et al.
AIDS Research and Human Retroviruses|April 25, 2000
Baseline HIV type 1 genotypic resistance to a newly added nucleoside analog is predictive of virologic failure of the new therapyK Van Vaerenbergh, K Van Laethem, E Van Wijngaerden, et al.
The Journal of Infection|June 24, 2008
HIV-1 infected patients older than 50 years. PISCIS cohort studyG Navarro, M M Nogueras, F Segura, et al.
Journal of Virus Eradication|June 18, 2021
Launching a multidisciplinary European collaboration towards a cure for HIV: The EU2Cure ConsortiumC Rokx, H A B Prins, L Vandekerckhove, et al.
Current HIV Research|February 15, 2019
Real World Patient-reported Outcomes in HIV-infected Adults Switching to EVIPLERA®, Because of a Previous Intolerance to cART. PRO-STR StudyD Podzamczer, N Rozas, P Domingo, et al.
Antiviral Research|November 28, 2009
Similar antiviral efficacy and tolerability between efavirenz and lopinavir/ritonavir, administered with abacavir/lamivudine (Kivexa), in antiretroviral-naïve patients: a 48-week, multicentre, randomized study (Lake Study)P Echeverría, E Negredo, G Carosi, et al.
Antiviral Therapy|June 22, 2001
Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-upA M Vandamme, F Houyez, D Bànhegyi, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 1, 2015
Effect of maraviroc on non-R5 tropic HIV-1: refined analysis of subjects from the phase IIb study A4001029M Surdo, C Alteri, M C Puertas, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 7, 2000
Comparison of immunologic restoration and virologic response in plasma, tonsillar tissue, and cerebrospinal fluid in HIV-1-infected patients treated with double versus triple antiretroviral therapy in very early stages: The Spanish EARTH-2 Study. Early Anti-Retroviral Therapy StudyF García, M M Alonso, J Romeu, et al.
Pageof 27

Showing results (241-250 of 263) with videos related to

Sort By:
Pageof 27
The Journal of Antimicrobial Chemotherapy|December 26, 2015
Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ARTS Lambert-Niclot, E C George, A Pozniak, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|September 13, 2012
Optimal timing for initiation of highly active antiretroviral therapy in treatment-naïve human immunodeficiency virus-1-infected individuals presenting with AIDS-defining diseases: the experience of the PISCIS CohortC Manzardo, A Esteve, N Ortega, et al.
AIDS Research and Human Retroviruses|April 25, 2000
Baseline HIV type 1 genotypic resistance to a newly added nucleoside analog is predictive of virologic failure of the new therapyK Van Vaerenbergh, K Van Laethem, E Van Wijngaerden, et al.
The Journal of Infection|June 24, 2008
HIV-1 infected patients older than 50 years. PISCIS cohort studyG Navarro, M M Nogueras, F Segura, et al.
Journal of Virus Eradication|June 18, 2021
Launching a multidisciplinary European collaboration towards a cure for HIV: The EU2Cure ConsortiumC Rokx, H A B Prins, L Vandekerckhove, et al.
Current HIV Research|February 15, 2019
Real World Patient-reported Outcomes in HIV-infected Adults Switching to EVIPLERA®, Because of a Previous Intolerance to cART. PRO-STR StudyD Podzamczer, N Rozas, P Domingo, et al.
Antiviral Research|November 28, 2009
Similar antiviral efficacy and tolerability between efavirenz and lopinavir/ritonavir, administered with abacavir/lamivudine (Kivexa), in antiretroviral-naïve patients: a 48-week, multicentre, randomized study (Lake Study)P Echeverría, E Negredo, G Carosi, et al.
Antiviral Therapy|June 22, 2001
Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-upA M Vandamme, F Houyez, D Bànhegyi, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 1, 2015
Effect of maraviroc on non-R5 tropic HIV-1: refined analysis of subjects from the phase IIb study A4001029M Surdo, C Alteri, M C Puertas, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 7, 2000
Comparison of immunologic restoration and virologic response in plasma, tonsillar tissue, and cerebrospinal fluid in HIV-1-infected patients treated with double versus triple antiretroviral therapy in very early stages: The Spanish EARTH-2 Study. Early Anti-Retroviral Therapy StudyF García, M M Alonso, J Romeu, et al.
Pageof 27